SCHEMBL6771995

SCHEMBL6771995

Clc1cccc2nc(N3CCNCC3)cnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.55
HTR3A P46098 5/20 0.51
ALDH1A1 P00352 4/20 0.51
HTR3E A5X5Y0 3/20 0.51
HTR3B O95264 3/20 0.51
HTR3D Q70Z44 3/20 0.51
HTR3C Q8WXA8 3/20 0.51
HTR2C P28335 5/20 0.50
ADRB1 P08588 5/20 0.50
KDM4E B2RXH2 4/20 0.50
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 3/20 0.50
HSD17B10 Q99714 3/20 0.50
HTR1A P08908 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
HTR7 P34969 2/20 0.50
HTT P42858 2/20 0.50
USP2 O75604 1/20 0.50
MAPK1 P28482 1/20 0.50
SLC6A4 P31645 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114532 0.79 NPC1 (0.66) HTR3AALDH1A1HTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL4056910 0.77 NPC1 (0.64) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL17043892 0.77 NPC1 (0.64) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL6776065 0.77 HTR3A (0.60) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL6777260 0.75 HTR3E (0.59) PTPN11HTR3AALDH1A1HTR3EHTR3B
SCHEMBL6350588 0.74 CHRNB2 (0.62) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL31058088 0.73 PTPN11 (0.65) PTPN11MAPK1
SCHEMBL31326693 0.72 ALDH1A1 (0.55) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL10219394 0.72 HRH4 (0.70) PTPN11HTR3AALDH1A1HTR3EHTR3B
SCHEMBL13666132 0.71 HCAR2 (0.53) HTR3AALDH1A1HTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A PTPN11 2298/4885HTR3A 2835/4885ALDH1A1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.